文献速递治疗药物监测与药物基因组学特殊人群用药

基于生理药代动力学模型评估伏立康唑CYP2C19表型指导的剂量调整

Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
PubMed 文献 · Clin Pharmacokinet · 2021-01-01

该研究利用生理药代动力学(PBPK)建模,针对不同CYP2C19表型优化伏立康唑单剂量模型并外推至稳态,评估与治疗范围的吻合度。结果显示标准剂量仅适用于正常代谢者(NM),中间代谢者(IM)和慢代谢者(PM)需分别降低日剂量50%和75%,快代谢者(RM)和超快代谢者(UM)需分别增加100%和300%。结论推荐根据CYP2C19表型个体化处方伏立康唑,并结合治疗药物监测指导剂量调整。

要点

  • 标准剂量仅适用于CYP2C19正常代谢者(NM),且可能受益于50-100%负荷剂量增加。
  • 中间代谢者(IM)和慢代谢者(PM)需分别降低日剂量50%和75%。
  • 快代谢者(RM)和超快代谢者(UM)需分别增加日剂量100%和300%。

核心结论

  • 伏立康唑临床处方应按CYP2C19表型个体化,并借助血药浓度治疗药物监测指导剂量调整。

研究设计与样本

  • 采用生理药代动力学(PBPK)建模,基于单剂量生物等效性研究和稳态观察浓度数据,针对每种CYP2C19表型优化伏立康唑单剂量模型并外推至稳态。

主要发现

  • 模型提示标准剂量可能仅适用于正常代谢者(NM),但NM可能受益于50-100%负荷剂量增加。
  • 中间代谢者(IM)和慢代谢者(PM)分别需要日剂量降低50%和75%。
  • 快代谢者(RM)和超快代谢者(UM)分别需要日剂量增加100%和300%。

关键数值与推荐

  • 荷兰药物遗传学工作组(DPWG)推荐CYP2C19超快代谢者(UM)或慢代谢者(PM)分别增加或减少50%剂量。
  • 临床药物遗传学实施联盟(CPIC)伏立康唑指南对上述表型仅推荐改变治疗,而非调整剂量。
  • PBPK模型优化后评估与伏立康唑治疗范围的吻合度,并据此提出各表型剂量调整方案。

临床怎么用

  • 临床处方伏立康唑前应明确CYP2C19表型,按表型选择初始日剂量和负荷剂量。
  • 用药后应开展血药浓度治疗药物监测,根据实测浓度进一步调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Controversy exists regarding dose adjustment in patients treated with voriconazole due to the severity of the infections for which it is prescribed. The Dutch Pharmacogenetics Working Group (DPWG) recommends a 50% dose increase or decrease for cytochrome P450 (CYP) 2C19 ultrarapid (UM) or poor (PM) metabolizers, respectively. In contrast, for the previous phenotypes, the Clinical Pharmacogenetics Implementation Consortium (CPIC) voriconazole guideline only recommends a change of treatment. Based on observed data from single-dose bioequivalence studies and steady-state observed concentrations, we aimed to investigate voriconazole dose adjustments by means of physiologically based pharmacokinetic (PBPK) modeling. METHODS: PBPK modeling was used to optimize voriconazole single-dose models for each CYP2C19 phenotype, which were extrapolated to steady state and evaluated for concordance with the therapeutic range of voriconazole. Based on optimized models, dose adjustments were evaluated for better adjustment to the therapeutic range. RESULTS: Our models suggest that the standard dose may only be appropriate for normal metabolizers (NM), although they would benefit from a 50-100% loading dose increase. Intermediate metabolizers (IMs) and PMs required a daily dose reduction of 50 and 75%, respectively. Rapid metabolizers (RMs) and UMs required a daily dose increase of 100% and 300%, respectively. CONCLUSION: The prescription of voriconazole in clinical practice should be personalized according to the CYP2C19 phenotype, followed by therapeutic drug monitoring of plasma concentrations to guide dose adjustment.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Zubiaur P, Kneller LA, Ochoa D, et al. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2021. PMID: 32939689. doi:10.1007/s40262-020-00941-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。